

Paper: PB.21.07.2017/13

NHS ENGLAND – BOARD PAPER

Title:

2016-17 Specialised Commissioning Committee (SSCC) annual report

Lead Director:

Noel Gordon, Chair of SSCC

Purpose of the paper:

To update the Board on the work of the SSCC in 2016-17.

Actions required from the Committee:

To note the content of the report.

2016/17 Specialised Services Commissioning Committee Annual Report

Introduction

1. The Committee provides advice to the Board on the development and implementation of NHS England's strategy for commissioning prescribed specialised services, providing assurance of quality, performance and value for money.

Committee members

2. The Committee has met eight times since April 2016. Membership has been amended during the year to reflect staff and organisational changes. The following table details core membership and the number of meetings attended by each member during the year:

Member	Number of eligible meetings attended during the year	Comments
Noel Gordon (Chair)	8/8	
Professor Sir John Burn	5/8	
Michelle Mitchell	4/6	Committee Member since May 2016.
Paul Baumann	8/8	
Ian Dodge	5/8	
Professor Sir Bruce Keogh	7/8	
Simon Stevens	5/8	
John Stewart	8/8	Director of Specialised Commissioning
Matthew Swindells	0/5	Member since July 2016

Committee attendees

3. Additional attendees have been invited to attend meetings to assist with Committee business. For 2016/17, these have included:
 - Clinical Director for Specialised Commissioning
 - Director of Strategy and Policy, Specialised Commissioning

Principal activities during the year

4. Over the year, the Committee has:
 - Overseen the development and implementation of:
 - a new strategic framework for specialised services, setting out expectations for delivering the FYFV and taking it forward through STPs
 - a new prioritisation process for new drugs and treatments
 - service reviews, including for high cost drugs and devices;
 - Overseen the launch of the joint consultation with NICE on technology appraisals and a consultation on NHS England's policies on service developments and individual funding requests;
 - Reviewed and agreed the routine commissioning of 33 new drugs and treatments;
 - Provided assurance and oversight for:
 - the new Cancer Drugs Fund
 - specialised commissioning financial plans for 2016/17 and 2017/18
 - ongoing assurance of operational decisions taken by NHS England's Specialised Commissioning Oversight Group (SCOG).

Planned activities during the coming year

5. The Committee's priority will be to continue supporting the implementation of the Strategic Framework for 2017/18. This will require the Committee to:
 - Provide assurance on how specialised commissioning is supporting improvements in patient care in relation to NHS England's priorities, particularly for mental health, learning difficulties and cancer
 - Provide assurance on financial control for specialised services and on achieving specialised services efficiency savings for 2016/17 to 2020/21
 - Oversee the implementation of place-based commissioning where appropriate
 - Oversee ongoing work around data and information, including implementation of RightCare for specialised commissioning
 - Consider which new treatments will be routinely commissioned by NHS England for 2017/18 and for 2018/19, taking advice from the Clinical Priorities Advisory Group (CPAG) and from SCOG
 - Oversee the Medicines Value Programme, which aims to identify potential opportunities to maximise value from medicines.